Here, results of the clonogenic assay revealed that BPR1K653 was effective (i.e. IC50<0.5 μM) against various types of cancer cells, including lung (A549), oral (HONE-1 and OECM-1) cervical (KB), colon (HT29), bladder (NTUB1) and leukemia/lymphoma (MV4-11 and IM9), regardless of their p53 status (Table 2). Here, TP53 is linked to cancer.